Beam Therapeutics
BEAM
Market cap $1.72B

17.06 USD

-0.38

2.18%

At close Jun 13, 4:00 PM EDT

After hours

17.11

+0.05

0.29%

1 day

-2.18%

5 days

-12.29%

1 month

-5.48%

3 months

-31.92%

6 months

-38.92%

Year to date

-30.93%

1 year

-32.41%

5 years

-36.46%

10 years

-9.01%

About: Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Employees: 502

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

113% more repeat investments, than reductions

Existing positions increased: 100 | Existing positions reduced: 47

100% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 4 (+2) [Q1 2025]

52% more call options, than puts

Call options by funds: $11.8M | Put options by funds: $7.81M

31% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 32

3.14% more ownership

Funds ownership: 98.36% [Q4 2024] → 101.5% (+3.14%) [Q1 2025]

3% more funds holding

Funds holding: 230 [Q4 2024] → 236 (+6) [Q1 2025]

2% less capital invested

Capital invested by funds: $2.02B [Q4 2024] → $1.99B (-$35.6M) [Q1 2025]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$25

47%

upside

Avg. target

$54

219%

upside

High target

$80

369%

upside

5 analyst ratings

4 positive

80%

1 neutral

20%

0 negative

0%

Guggenheim Debjit Chattopadhyay	222%upside $55	Buy Maintained	7 May 2025
Wells Fargo Yanan Zhu	310%upside $70	Overweight Maintained	7 May 2025
Barclays Gena Wang	47%upside $25	Equal-Weight Maintained	7 May 2025
HC Wainwright & Co. Patrick Trucchio	369%upside $80	Buy Reiterated	7 Apr 2025
B of A Securities Alec Stranahan	146%upside $42	Buy Upgraded	28 Mar 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about BEAM published over the past 30 days

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to

Zacks Investment Research

Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?

Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?

Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?

Zacks Investment Research

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

Beam Therapeutics rises after the FDA grants orphan drug status to its gene-editing therapy BEAM-101 for sickle cell disease.

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD).

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation of a guide RNA and an mRNA encoding a base editor designed to correct the disease-causing mutation in patients with alpha-1 antitrypsin deficiency (AATD). AATD is an inherited genetic disorder that affects the lungs and/or liver, leading to early onset emphysema and liver disease, and for which there is significant unmet need for effective therapies that can treat the entire spectrum of disease.

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of BEAM-101

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025, at 11:00 a.m.

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation of a guide RNA and an mRNA encoding a base editor designed to correct the disease-causing mutation in patients with alpha-1 antitrypsin deficiency (AATD). AATD is an inherited genetic disorder that affects the lungs and/or liver, leading to early onset emphysema and liver disease, and for which there is significant unmet need for effective therapies that can treat the entire spectrum of disease.

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Zacks Investment Research

BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates

Beam Therapeutics incurs a wider-than-expected loss in the first quarter. The company remains focused on pipeline development.

BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates

The Motley Fool

Why Beam Therapeutics Stock Tanked on Tuesday

Precision gene-editing company Beam Therapeutics (BEAM -19.68%) had a Tuesday to forget on the stock market. Following the release that morning of its latest set of quarterly results, the shares raced downwards to a more than 19% loss on the day.

Why Beam Therapeutics Stock Tanked on Tuesday

See News Rankings

Charts implemented using Lightweight Charts™